

**The 2nd Manchester Cystic Fibrosis
Conference:
Facing the Challenges of Today**

**Stoller Hall - Chetham's School of Music
Thursday 26th April 2018**



Welcome

It is our great pleasure to welcome you to Manchester to the 2nd Manchester Cystic Fibrosis Conference. The theme of this year's conference concerns some of the most pertinent issues in current CF care including increasing numbers of patients, infection control and utilising registry data to improve centre based care. We are delighted to have a prestigious international faculty to share their expertise on a range of topics.

We hope that all members of the multi-disciplinary team will find topics that will be stimulating and thought provoking. We encourage your participation via the event app and Sli.do which can be used to ask questions and vote in polls. The workshops have been designed to offer an interactive and innovative space for all delegates. We hope that by sharing your experience and insights we can all work more effectively to tackle the challenges of today.

Finally, we are very grateful to our sponsors for helping support this meeting and to Vertex in particular who provided an unrestricted educational grant for the event. Also to The Christie School of Oncology Events Team for their invaluable help and support in the organisation of this meeting.

We hope that the meeting will provide lots of opportunities to interact with colleagues and opportunities for learning.

We look forward to welcoming you.

Dr Peter Barry - Consultant Respiratory Physician, Manchester Adult CF Centre

Professor Andrew Jones - Director, Manchester Adult CF Centre


Dr Alex Horsley - Consultant, Manchester Adult CF Centre

Dr Helen Oxley - Consultant Clinical Psychology, Manchester Adult CF Centre



This meeting has been kindly supported by an unrestricted educational grant from Vertex pharmaceuticals limited

Floor Plan



For Wi-Fi access:

TheStollerHall

Password: CF2018

Faculty



Dr Peter Barry – Consultant Respiratory Physician, Manchester Adult Cystic Fibrosis Centre

Dr Barry is a Consultant Respiratory Physician with a special interest in cystic fibrosis. He graduated from University College Cork in 2002 and completed higher specialist training in Respiratory and General Internal Medicine in the Republic of Ireland. He has worked as a clinical research fellow in cystic fibrosis in the National Referral Centre for Cystic Fibrosis in Ireland based in St. Vincent's University Hospital in Dublin culminating in the award of an MD degree. He joined the University

Hospital of South Manchester in 2012 and works as a Consultant Respiratory Physician in the Manchester Adult Cystic Fibrosis Centre. He is an Honorary Senior Lecturer with the University of Manchester. He has a keen interest in clinical research in CF and in particular the clinical applications of novel therapies. He has been an invited speaker at numerous national and international meetings particularly in the area of CFTR modulation. He has served as a clinical expert on NICE evaluations of new therapies in CF. He is the co-chair of the Manchester Cystic Fibrosis Conference.



Dr Alex Horsley – Senior Lecturer, University of Manchester and Consultant Manchester Adult CF Centre

Dr Horsley is an NIHR-funded clinical academic at the University of Manchester and consultant at the Manchester Adult Cystic Fibrosis Centre. He is academic lead for the CF Centre where he leads a programme of basic science and clinical research as part of The University of Manchester NIHR Biomedical Research Centre in Respiratory Medicine. His main work focuses on novel technologies and clinical applications for lung clearance index (LCI), how this relates

to clinical outcomes and imaging, and encompasses all age groups from infants to adults. He is deputy director of the NIHR Manchester Clinical Research Facility at Wythenshawe Hospital, and leads a wide range of clinical trials in CF, including phase 1, both as principal and chief investigator. Dr Horsley has contributed to national policy on CF medications, to international guidelines on multiple breath wash out, and is chief editor and author of the Oxford University Press Handbook on CF.



Professor Andrew M Jones – Director, Manchester Adult Cystic Fibrosis Centre

Professor Andrew M Jones is the Director of the Manchester Adult Cystic Fibrosis Centre. The Manchester Adult Cystic Fibrosis Centre is one of the largest in the country and currently provides care for over 450 adults with cystic fibrosis from the North West of England. Prof Jones is actively involved in clinical research and has published over 100 papers and co-authored a number of national guidelines for cystic fibrosis, including the recent NICE clinical guidelines for CF care. Prof Jones is a

member of the Clinical Reference Group for Specialised Respiratory Services for NHS England and is also a Trustee of the Cystic Fibrosis Trust. He participates in work for the US Cystic Fibrosis Foundation Data Safety Monitoring Board and as a steering committee member for a number of national multicentre studies.



Dr Helen Oxley – Consultant Clinical Psychologist, Manchester Adult Cystic Fibrosis Centre

Helen Oxley is a Consultant Clinical Psychologist, Manchester Adult Cystic Fibrosis Centre. She completed training as a clinical psychologist in 1992, and has worked in the speciality of physical health for most of her career to date. Helen is currently Consultant Clinical Psychologist at the Manchester Adult Cystic Fibrosis Centre where she leads a small psychology team, and has worked within this large CF unit since 1997. She has contributed to several texts on psychological aspects of

CF and frequently presents at CF conferences on a wide variety of psychological issues for people with CF, their families and their healthcare teams. Helen also provides a wide-ranging psychological therapy service to patients at all stages of CF and also works closely with the MDT to optimise psychological care for people with CF, through service development, consultation, joint working, research and training. Helen is also current co-chair of the UK Psychosocial Professionals in CF, the group for all psychologists and social workers working in CF centres in the UK.

Speakers



Professor A Kevin Webb FRCP – Previous Clinical Director, Manchester Adult Cystic Centre

Professor Webb trained as a doctor in London and then immigrated to the North West. With Mary Dodd in 1982 he established an adult Cystic Fibrosis Unit in the North West. Professor Webb is involved with the clinical care of CF adults and the politics and business management of the unit. Professor Webb has sat on National and International Committees engaged in improving CF care. Professor Webb has gone part time and visits the CF Unit 3 days a week as his social club.



Professor Scott Bell - Executive Director – Research, MNHHS and a Senior Physician of the Adult CF Centre at TPCH

Professor Scott Bell is Executive Director – Research, MNHHS and a Senior Physician of the Adult CF Centre at TPCH (>300 patients) where he has worked since 1996. He is currently the Editor-in-Chief of the Journal of Cystic Fibrosis. He leads the Lung Bacteria Laboratory at QJMR Berghofer Medical Research Institute in Brisbane. Scott has over 180 peer reviewed publications and has received grant support in excess of \$10 million over the past 10 years. His research interests include the CF microbiology, acquisition pathways for human infection and he has a long history of supporting multi-disciplinary research.



Professor Edward McKone – Consultant Respiratory Physician, National Referral Center for Adult CF, St Vincent’s University Hospital and Clinical Professor, UCD

Professor Edward McKone is a Consultant Respiratory Physician in the National Referral Center for Adult Cystic Fibrosis, St. Vincent’s University Hospital and Clinical Professor, University College Dublin. A graduate of Trinity College Dublin, he completed his initial respiratory training including doctoral thesis in St. Vincent’s University Hospital. He subsequently entered a

3 year fellowship in Pulmonary and Critical Care Medicine at the University of Washington, Seattle followed by 4 years on faculty as an Assistant Professor in Pulmonary and Critical Care Medicine. During his time in Seattle, he completed a MSc in Genetic Epidemiology. In 2006, he was appointed to St. Vincent’s University Hospital, Dublin where he is currently a respiratory physician with clinical and research interests in the areas of cystic fibrosis, clinical epidemiology and bronchiectasis. He has been the Director of the European CF Patient Registry and is the current Director of the Irish CF Patient Registry.



Professor Chris van der Gast – Professor of Microbiology, Manchester Metropolitan University

Chris is Professor of Microbiology at Manchester Metropolitan University. He is also visiting Professor of Microbial Ecology at the University of Warwick and Fellow in Microbiomics at the NERC Centre for Ecology & Hydrology. His research is focused on the role of infection microbiota in chronic lung disease progression. In order to unravel the complexity of microbiomes in lung disease, he exploits and adapts models, theories, and principles from traditional ecology, coupled with ever improving

developments in high-throughput sequencing technologies.



Dr Miles Denton – Consultant Microbiologist, Leeds Teaching Hospital NHS Trust

Dr Miles Denton is a consultant microbiologist at Leeds Teaching Hospitals NHS Trust and has had a long standing interest in CF Microbiology. His MD thesis was entitled “The epidemiology of *Stenotrophomonas maltophilia* isolated from children with cystic fibrosis” and, along with colleagues from the Leeds Adult and Paediatric CF Centres, he has contributed to over 40 publications in peer reviewed journals linked to CF Microbiology. He has contributed to a number of UK CF Trust Working Parties developing guidelines linked to antimicrobial therapy and Infection Prevention in CF and chaired the group that developed laboratory standards for CF Microbiology. He has previously been a member of the Scientific Committee of the European CF Conference and is currently co-chair of the Microbiology sub-group of the ECFS Clinical Trials Network.



Professor Havi Carel – Professor of Philosophy, University of Bristol

Dr Havi Carel is Professor of Philosophy at the University of Bristol, where she also teaches medical students. Her research examines the experience of illness and of receiving healthcare. She is currently completing a monograph for Oxford University Press, provisionally entitled *Phenomenology of Illness*. She was recently awarded a Senior Investigator Award by the Wellcome Trust, for a five year project entitled ‘The life of breath’ (with Prof Jane Macnaughton, Durham University). She has written on the embodied experience of illness, wellbeing within illness and patient-clinician communication in the *Lancet*, *BMJ*, *Journal of Medicine and Philosophy*, *Theoretical Medicine and Bioethics*, *Philosophia* and in edited collections.



Dr Samantha Phillips - Clinical Psychologist, Bristol Adult and Paediatric Services

Dr Phillips is a clinical psychologist in the paediatric and adult CF services in Bristol where she has worked for the last 10 years developing the psychology service for the patients in the South West. She is committee member of the UK psychosocial professionals group and has an active interest in ensuring that they develop ways to best help patients to adjust to an ever changing world of CF medical care so that all patients are encouraged to live the lives they want to.



Fiona Cathcart - Clinical Specialty Lead for the adult CF therapies team, Royal Brompton Hospital

Fiona is the Clinical Specialty Lead for the adult CF therapies team at the Royal Brompton Hospital. She started her career at Southampton University Hospital before moving to the Royal Brompton in 2010. Fiona completed a Master's degree in Advanced Cardiorespiratory Physiotherapy at the University of Hertfordshire in 2015. Her areas of special interest are quality improvement and innovation in healthcare, non-

invasive ventilation and end of life care.



Professor Helge Hebestreit – Professor of Paediatrics and Director of the CF Centre, Würzburg, Germany

Helge Hebestreit, MD, Professor of Paediatrics is currently director of the CF centre in Würzburg, Germany and Vice Chair of Paediatrics.

Professor Hebestreit received his medical training in Würzburg between 1982 and 1989 and continued his education in Würzburg for specialisations in paediatrics, sports medicine, and paediatric pulmonology. During a 2-year post-doctoral fellowship with Prof. Dr. Oded Bar-Or

from McMaster University in Hamilton/Ontario, Canada, Prof. Hebestreit participated in research involving children with chronic health conditions and physical exercise. This topic remained the focus of his scientific interest thereafter. Since 1998, Prof. Hebestreit studied together with his wife, a paediatrician running the CF clinic in Würzburg, the effects of physical exertion and physical training on patients with cystic fibrosis. Prof. Hebestreit is the coordinator of the Exercise Working Group of the European Cystic Fibrosis Society and principal investigator of the international multi-centre study ACTIVATE-CF which actually assesses the effects of an exercise program in CF.



Professor Alan Smyth - Professor of Child Health, University of Nottingham and Honorary Consultant in Paediatric Respiratory Medicine, Nottingham University Hospitals NHS Trust

Professor Alan Smyth is Professor of Child Health at the University of Nottingham and Honorary Consultant in Paediatric Respiratory Medicine at Nottingham University Hospitals NHS Trust. His major research interests are in novel ways of treating infection in CF and strategies to detect and minimise the adverse effects of treatment. He has led a James Lind Alliance Priority Setting Partnership

which worked with clinicians and patients to decide the top 10 priorities for clinical research in CF. Prof Smyth is Co-ordinating Editor of the Cochrane Cystic Fibrosis & Genetic Disorders Group and Joint Editor in Chief of Thorax. When not working, he is a keen cyclist and pilot.



Tracey Daniels - Specialist Physiotherapist for Cystic Fibrosis, York Hull Adult Cystic Fibrosis Centre and guest lecturer, Leeds Beckett University

Tracey graduated from the University of Manchester in 1999, completed an MSc in management of long-term health conditions in 2009 and qualified as a non-medical prescriber in 2013. She has worked in various CF centres across the UK and is currently the specialist Physiotherapist for Cystic Fibrosis at the York Hull adult CF centre and also guest lecturer at the Leeds Beckett University.

Tracey was editor for the CF trust/ACPCF physiotherapy guidelines, lead for the Cystic Fibrosis section of the British Thoracic Society guidelines for the Physiotherapy management of the adult, medical, spontaneously breathing patient and has also published within the areas of physiotherapy management of Cystic Fibrosis, adherence and nebulised medication. Tracey was a member of the steering committee for the recent James Lind CF research priority setting partnership and hopes that this work will highlight the need to be innovative and collaborative about physiotherapy research.



Lisa Morrison - Principal Physiotherapist, West of Scotland Adult CF Unit

Lisa has been working as a physiotherapist in Cystic Fibrosis for 23 years; initially in paediatrics and for the last 17 years with adult CF patients. Lisa is the Principal Physiotherapist at the West of Scotland Adult CF unit in Glasgow. She is also currently the Chair of the CF physiotherapy clinical interest group ACPCF. She has contributed to and co-edited the 2017 “Standards of Care & Good Clinical Practice” for the physiotherapy management of CF. Lisa led on the 2010 UK “National

audit of physiotherapy standards of care” and has recently completed the re-audit evaluating the developments in service provision across CF centres in the UK. Lisa is the physiotherapy representative on The UK Cystic Fibrosis Trust Mycobacterium abscesses Infection Control Working Group.



Dr Rob Lord - Respiratory Medicine Trainee, North West Deanery

Rob qualified from The University of Manchester in 2006. He has completed medical training locally in hospitals in Manchester and Liverpool, as well as a period of 18 months slightly further afield in Newcastle, Australia. Currently Rob is a respiratory medicine trainee based in the Northwest deanery. He went out for his training program from 2015-2018 and worked at the Manchester adult CF centre for 3 years as a clinical fellow. During his time here he undertook a PhD project examining the relationship between gastro-oesophageal reflux and CF lung disease.



Dr William Flight - Consultant in Respiratory Medicine, Oxford University Hospitals NHS Foundation Trust and Director, Oxford Adult Cystic Fibrosis Centre

William graduated from the University of Sheffield in 2002. After house jobs in Stoke-on-Trent and Christchurch, New Zealand he trained in general and respiratory medicine in the North West of England. He spent three years as a clinical research fellow at the Manchester Adult Cystic Fibrosis Centre. During this time he was awarded a PhD from the University of Manchester for research into the role of viral respiratory infections in adults with CF.

William took up his current post as a consultant in respiratory medicine at Oxford University Hospitals NHS Foundation Trust in 2014. He is the director of the Oxford Adult Cystic Fibrosis Centre and oversaw the relocation of the service to the John Radcliffe Hospital in 2016. He has published on various aspects of CF lung disease and has on-going research interests in respiratory microbiology and iron homeostasis in CF.



Prof Martin Walshaw - Consultant Chest Physician and Director of Specialist Regional CF Clinic, Liverpool Heart and Chest Hospital

Professor Martin Walshaw is a Consultant Chest Physician at the Liverpool Heart and Chest Hospital and Director of the Specialist Regional Adult CF Clinic there, which he founded in 1993 and which now caters for over 330 adults from Merseyside, North Wales, Cheshire, and the Isle of Man. He is past Chair of the British Thoracic Society Cystic Fibrosis Specialist Advisory Group, Chair of the UK CF Peer Review

Oversight Board, and Chaired the NICE committee writing guidelines for CF Care in the UK. Professor Walshaw is heavily involved in medical education and is a Senior PACES Examiner and Secretary of the Respiratory Specialist Certificate Examination Board for the RCP. He has published over 100 peer reviewed papers and his major research interests include cross infection in CF and developments in CFRD. He was appointed Honorary Professor of Medicine at Liverpool University in 2014 in recognition of his achievements.



Professor Felix Ratjen - Division Chief of Paediatric Respiratory Medicine, Hospital for Sick Children and Professor of Paediatrics, University of Toronto

Dr. Felix Ratjen is also Senior Scientist at the Research Institute in the Translational Medicine research program. He is co-leading the CF centre at SickKids and Medical Director of the Clinical Research Unit.

Dr. Ratjen completed a majority of his medical education in Germany, along with a research fellowship at the Children's Hospital in Boston. He subsequently worked at the University of Essen, where he was appointed Deputy Chief of the Department of Paediatrics in 1998 and Professor of Paediatrics in 2001. Until 2005 he was the chief executive of the scientific board of the German CF foundation before relocating in Canada in the same year. He is on the organising committees of the major respiratory meetings (American Thoracic Society, European Respiratory Society and the North American CF conference), works on multiple grant review panels and is a member of several editorial boards including the American Journal of Respiratory and Critical Care Medicine, Thorax, Pediatric Pulmonology and the Journal of Cystic Fibrosis.



Prof. Isabelle Fajac (MD, PhD) - Head of the Cystic Fibrosis Research Laboratory at Sorbonne Paris Cité University

Prof. Isabelle Fajac (MD, PhD) received her medical training, post-graduate training and further specialisation in respiratory medicine at Assistance Publique-Hôpitaux de Paris and Paris Descartes University. She has completed a PhD on cystic fibrosis gene transfer at INSERM and Paris Descartes University. She is a pulmonologist and Professor of Physiology affiliated with the Cochin Hospital Cystic Fibrosis Centre, which cares for more than 400 adult cystic

fibrosis patients and is the largest Cystic Fibrosis Centre in France. Prof. Isabelle Fajac has been Principal Investigator of several institutional and pharmaceutical clinical trials on cystic fibrosis and is Head of the Cystic Fibrosis Research Laboratory at Sorbonne Paris Cité University. She has been the Chair of ECFS-Clinical Trials Network from 2012 to 2014 and is the incoming ECFS President.

Chairs



Agnes Tansinda - Senior Social Worker, Manchester Adult Cystic Fibrosis Centre

Agnes is the Senior Social Worker at The Manchester Adult Cystic Fibrosis Centre where she has worked since 2011, leading a small team of five social workers. She is also social work lead and conference coordinator of the UK Psychosocial Professionals in CF, the group for all psychologists and social workers working in CF centres in the UK. She has an MSc in social work and 18 years experience as a social worker with older people and young adults both with the council and NHS in a wide range of

settings including community and hospital.



Heather Green – Consultant Respiratory Physician, Manchester Adult Cystic Fibrosis Centre

Heather graduated from the University of Manchester in 2002 and is a Consultant Respiratory Physician at the Manchester Adult Cystic Fibrosis Centre. She completed her MD on the role of emerging pathogens in adults with cystic fibrosis in 2015 and this continues to be her research interest.



Hannah Langman - Clinical Specialist Physiotherapist, Manchester Adult Cystic Fibrosis Centre

Hannah is a Clinical Specialist Physiotherapist and has worked at MACFC for 17 years in both inpatient and outpatient settings. She is currently based in the outpatient clinics and is the physiotherapy lead for delivery of high cost inhaled drugs.

She is also a member of the BTS Specialist Advisory Group for CF and has recently taken on the Association of Chartered Physiotherapists in CF (ACPCF) role as UK representative for the International Physiotherapy Group in CF.



Dr Rowland Bright-Thomas - Consultant Respiratory Physician, Manchester University NHS Foundation Trust and Honorary Senior Lecturer in Respiratory Medicine, Manchester University

Dr Rowland Bright-Thomas is a Consultant Respiratory Physician at Manchester University NHS Foundation Trust and Honorary Senior Lecturer in Respiratory Medicine at Manchester University. He undertook his MD thesis on pulmonary artery pressure and ventricular function in adults with cystic fibrosis and works in a large multidisciplinary cystic fibrosis centre caring for 450 CF adults. His interests include late presentations, non-pulmonary complications and non - invasive ventilation in CF.



Amanda Brennan - Consultant in Respiratory Medicine, Manchester Adult Cystic Fibrosis Centre

Dr Brennan is a Consultant in Respiratory Medicine with a specialist interest in Cystic Fibrosis. She qualified from Nottingham University in 1995 and completed speciality training in London. She spent 3 years as a research fellow at St George's Hospital and The Royal Brompton Hospital researching the effect of Cystic Fibrosis Related Diabetes on respiratory disease and was awarded a PhD. She was awarded a CF Trust Clinical Fellowship at the Manchester

Adult Cystic Fibrosis Centre in 2006. She became a Consultant at the Manchester Adult Cystic Fibrosis Centre in 2009. She has published on aspects of Cystic Fibrosis Related Diabetes and has been invited to speak both nationally and internationally.



Dr Francis Gilchrist - Senior Lecturer and Consultant in Paediatric Respiratory Medicine, Keele University/University Hospitals of North Midlands

Dr Francis Gilchrist qualified from University of Manchester with Honours in 2002. He undertook his General Paediatric training in the North West Deanery before moving to the West Midlands to complete his Paediatric Respiratory training. Post CCT he worked as a Clinical Fellow at the Manchester Adult CF Centre. He was awarded his PhD by Keele University in 2014 and is currently Senior Lecturer

and Consultant in Paediatric Respiratory Medicine at Keele University / University Hospitals of North Midlands. His roles include Paediatric Director of the North West Midlands Cystic Fibrosis Centre and Trustee for the British Lung Foundation.

Agenda

09:00 **Registration and coffee**

09:45 Session 1: Addressing the challenges of modern CF care

Chairs: Dr Alex Horsley & Prof Helge Hebestreit

09:55 Developing state-of-the-art CF care

Prof Kevin Webb

10:15 Coping with increased patient numbers

Prof Scott Bell

10:50 How we use registries to improve care: Potentials and pitfalls

Prof Ed McKone

11:25 **Coffee and poster viewing**

Workshops 11:50-13:20

1) Infection, AUDITORIUM - Dr Heather Green and Prof Felix Ratjen

Why we're doing infection control all wrong—**Prof Scott Bell**

What have we learnt from molecular techniques, and what have we not—**Prof Chris van der Gast**

Targeting the complexity of airway microbiology—two birds, one stone? - **Dr Miles Denton**

2) Psycho-social, CAROLE NASH - Helen Oxley and Agnes Tansinda

The philosophy of breathlessness—**Prof Havi Carel**

Preparing for life as an adult with CF—**Dr Samantha Phillips**

How do we get the ceiling of care right in CF? - **Fiona Cathcart**

3) Physiotherapy, REHEARSAL ROOM - Hannah Langman and Dr Peter Barry

What we need to do for exercise prescription—**Prof Helge Hebestreit**

Matching research needs to patient expectation—**Prof Alan Smyth/Tracey Daniels**

Infection control and the physiotherapist—new challenges, potential solutions—**Lisa Morrison**

4) Extra-pulmonary, REHEARSAL ROOM - Dr Fran Gilchrist and Dr Rowland Bright-Thomas

The impact of Gastro-oesophageal reflux—**Dr Rob Lord**

Iron deficiency in CF—when and how should we investigate and treat? - **Dr William Flight**

Renal disease in CF—a ticking time bomb? - **Prof Martin Walshaw**

13:20 **Lunch, coffee and poster viewing**

Session 2: Emerging challenges in CF care

Chairs: Prof Andrew Jones & Dr Amanda Brennan

14:25 Adherence and adolescence

Prof Felix Ratjen

15:00 Challenges for patients with CFTR modulation

Dr Peter Barry

15:35 Ensuring next generation therapies are available to all

Prof Isabelle Fajac

16:10 **Closing remarks and poster award—Prof Andrew Jones**

With Special Thanks



This meeting has been kindly supported by an unrestricted educational grant from Vertex pharmaceuticals limited

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases.

In addition to clinical development programmes in CF, Vertex has more than a dozen ongoing research programmes focused on the underlying mechanisms of other serious diseases.

Founded in 1989 in Cambridge, Mass., USA, Vertex's headquarters is now located in Boston's Innovation District. Today, the company has research and development sites and commercial offices in the United States, Europe, Canada and Australia.

Vertex is consistently recognised as one of the industry's top places to work, including being named to *Science* magazine's Top Employers in the life sciences ranking for eight years in a row.

Platinum Sponsor



People and ideas for innovation in healthcare

Chiesi Limited is the UK affiliate of the international, privately-owned pharmaceutical company, based in Parma, Italy. Chiesi is dedicated to the research, development and sales of innovative, therapeutic prescription medicines in the field of respiratory, neonatology, transplant medicine and rare diseases. The Company was founded in 1935, as a family firm. Chiesi spans the globe, employing more than 4,800 people in 26 affiliates worldwide and sells its products in more than 70 countries.

We embrace innovation which is a constant driver to our continued success. Products wholly, or partially, developed by Chiesi account for three quarters of our sales, with continuous investment in Research and Development.

Chiesi has a portfolio of cystic fibrosis products within Special Care, for which Chiesi has strong ambitions to develop and acquire new medicines. We are committed to providing education and support to cystic fibrosis specialists and patients throughout the UK via a number of organisations.

For more information about Chiesi Limited please visit chiesi.uk.com

With special thanks to all our sponsors who have supported the conference. The supporting companies will be exhibiting with trade stands. They have had no input into the agenda or selection of topics or speakers.

Sponsors



Mylan

Mylan ranks among the leading global generic and specialty pharmaceutical companies. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership.

In the UK, Mylan has one of the largest portfolio of generic and branded generic drugs, offering an extensive range of dosage forms and delivery systems. At Mylan we have one global quality standard in everything we do. Our internal teams conduct reviews of all products, start to finish. No matter where in the world they are made.

Why such high standards? Because we truly care about the people who will be helped by the medicines we make. And we believe in earning that trust from physicians, pharmacists, other health care professionals and patients, every day. This is why we say, "Our Mylan is Your Mylan."



Gilead

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North and South America, Europe and Asia Pacific.

Gilead has had no input into the content of the materials used at this conference.



PARI Medical Ltd

PARI develop solutions for people suffering from respiratory diseases, in the form of high-quality, reliable devices. Voted 'Brand of the Century' in 2016 in the field of respiratory therapy by Deutsche Standards, PARI has been a leading manufacturer within the respiratory field for over 100 years.

PARI's mission is to improve the lives of those affected by respiratory diseases and those who provide care to them. This is reflected in PARI's comprehensive portfolio of innovative products and services.

PARI products include:

- the eFlow[®] *rapid* electronic nebuliser
- the PARI SINUS for treating the upper airways
- MucoClear[®] hypertonic saline

www.pari.com



medicines
evaluation unit

Medicines Evaluation Unit - An MHRA Phase 1 accredited site


The Medicines Evaluation Unit (MEU) is one of the UK's leading Clinical Research Organisations, based on the Wythenshawe Hospital site within a state-of-the-art, 36 bed facility.

We are affiliated with the Manchester Adult Cystic Fibrosis Centre, have the chief investigator capability and have established links with PIC sites at other CF centres.

MEU's bespoke database and trial management system ICARUS, contains over 100 Cystic Fibrosis patients who actively participate in clinical research. MEU have completed numerous Phase I Cystic Fibrosis studies and dosed dozens of patients.

For more information please visit: www.meu.org.uk

Floor Plan



For Wi-Fi access:

TheStollerHall

Password: CF2018



